Cimiracemoside C NEW
| Price | $54 | $127 | $198 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-14 |
Product Details
| Product Name: Cimiracemoside C | CAS No.: 256925-92-5 |
| Purity: 99.73% | Supply Ability: 10g |
| Release date: 2024/11/14 |
Product Introduction
Bioactivity
| 名稱 | Cimiracemoside C |
| 描述 | Cimiracemoside C (Cimicifugoside M) is an active component of Cimicifuga racemosa. It activates AMPK and has the potential activity against diabetes. |
| 體外活性 | Ze 450 and some of its components (23-epi-26-deoxyactein, protopine and Cimiracemoside C) were investigated in vitro for their effects on AMP-activated protein kinase (AMPK) compared to metformin in HepaRG cells. Ze 450 (given orally (PO) and intraperitonally (IP)), metformin (PO) and controls were given over 7 days to 68 male ob/ob mice. Glucose and insulin concentrations were measured at baseline and during an oral glucose tolerance test (OGTT). Ze 450 and its components activated AMPK to the same extent as metformin. In mice, Ze 450 (PO/IP) decreased significantly average daily and cumulative weight gain, average daily food and water intake, while metformin had no effect. In contrast to metformin, PO Ze 450 virtually did not change maximum glucose levels during OGTT, however, prolonged elimination. Ze 450 administered PO and IP decreased significantly post-stimulated insulin, whereas metformin did not. HOMA-IR index of insulin resistance improved significantly after IP and PO Ze 450 and slightly after metformin. In summary, the results demonstrate that Ze 450 reduced significantly body weight, plasma glucose, improved glucose metabolism and insulin sensitivity in diabetic ob/ob mice. In vitro experiments suggest that part of the effects may be related to AMPK activation. |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 6.21 mg/mL (10 mM) |
| 關(guān)鍵字 | AMP-activated protein kinase | inhibit | Cimiracemoside C | Inhibitor | AMPK |
| 相關(guān)產(chǎn)品 | Phenformin hydrochloride | AICAR | Doxorubicin hydrochloride | Adenosine monophosphate | Adenosine 5'-monophosphate monohydrate | Methyl cinnamate | A-769662 | Metformin hydrochloride | Chitosan oligosaccharide | Buformin hydrochloride | HTH-01-015 | AMPK activator 4 |
| 相關(guān)庫(kù) | 抗癌天然產(chǎn)物庫(kù) | 萜類天然產(chǎn)物庫(kù) | 經(jīng)典已知活性庫(kù) | 中藥單體化合物庫(kù) | 激酶抑制劑庫(kù) | 植物來(lái)源化合物庫(kù) | 糖類及苷類化合物庫(kù) | 高通量篩選天然產(chǎn)物庫(kù) | 抗衰老化合物庫(kù) | 古代經(jīng)典名方目錄分子庫(kù) |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $420.00/1g |
VIP3Y
|
Hebei Dangtong Import and export Co LTD
|
2024-09-13 | |
| $0.00/1kg |
VIP1Y
|
Shanghai Affida new material science and technology center
|
2024-05-06 | |
| $0.00/1g |
VIP1Y
|
Shaanxi Cuikang Pharmaceutical Technology Co., Ltd
|
2024-03-14 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY